Does Ozempic work differently in diabetic vs. non-diabetic patients?

What did @caitlanashlee actually say?

Honestly, not much that can be fact-checked. The transcript is song lyrics, not health commentary. The caption, though, raises a real question: does Ozempic (semaglutide) work differently in people with type 2 diabetes compared to people without it? She also notes she is "not dropping weight like others show" and says she is "learning things." That caption is the only substantive content here.

To be clear: the video's spoken content offers zero medical claims. The fact-check below addresses the question she raised in her caption, because it is a genuinely important one that many GLP-1 users are asking right now.

Does the science back this up?

Yes, there is real evidence that semaglutide behaves differently depending on whether you have type 2 diabetes, and the weight loss difference is significant. People without diabetes tend to lose more weight on the same drug.

The SUSTAIN trials, which studied semaglutide in people with type 2 diabetes, showed average weight loss of roughly 4 to 6 kg over 30 weeks at the 1 mg dose (Marso et al., 2016, New England Journal of Medicine). Compare that to the STEP 1 trial, which studied semaglutide 2.4 mg in people with obesity but without diabetes, and found average weight loss of about 14.9% of body weight over 68 weeks (Wilding et al., 2021, New England Journal of Medicine). The dose is different, yes, but the metabolic context matters independently. People with type 2 diabetes have underlying insulin resistance, altered glucagon secretion, and often take other medications that can partially blunt weight response. That is not speculation; it is documented in the STEP 2 trial, which specifically compared outcomes in people with type 2 diabetes and found weight loss was approximately half that seen in non-diabetic participants using similar doses (Davies et al., 2021, The Lancet).

What did they get wrong (or right)?

She did not get anything wrong, technically, because she did not make a direct claim. Credit where it is due: asking "I wonder the effects" is more intellectually honest than the average GLP-1 TikTok, which tends to confidently assert outcomes with no nuance.

Her personal observation that she is not losing weight like others show is consistent with what the data actually says about diabetic patients on GLP-1 therapy. If she is using Ozempic for diabetes management, slower or less dramatic weight loss is not a failure of the drug or her behavior. It reflects a genuinely different physiological starting point.

What is missing from her video is any acknowledgment that the "others" she references are likely seeing results from Wegovy, the 2.4 mg formulation of semaglutide approved specifically for weight management, not Ozempic, which tops out at 1 mg and is approved for glycemic control. That distinction matters a lot when you are comparing results.

What should you actually know?

If you have type 2 diabetes and are on Ozempic, do not benchmark your results against non-diabetic people using Wegovy or tirzepatide. You are comparing different drugs, different doses, and different metabolic contexts.

Several factors reduce weight loss response in people with type 2 diabetes specifically: higher baseline insulin resistance, concurrent use of insulin or sulfonylureas (which promote weight gain), and longer duration of metabolic dysfunction. A 2022 analysis published in Diabetes, Obesity and Metabolism (Rubino et al.) found that diabetes status was one of the strongest predictors of attenuated weight loss on semaglutide.

This does not mean GLP-1 therapy is not working. Glycemic improvement, cardiovascular risk reduction, and kidney protection are all documented benefits of semaglutide in diabetic patients that have nothing to do with the number on the scale. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed a 20% reduction in major cardiovascular events in non-diabetic patients with obesity, but the LEADER trial (Marso et al., 2016) showed meaningful cardiovascular benefit in diabetic patients with liraglutide too. The drug is doing things you cannot see.

The bottom line

The caption raises a real and underexplored question. The answer is: yes, the diabetic vs. non-diabetic distinction is one of the most clinically meaningful variables in predicting GLP-1 weight loss response. Slower weight loss in a diabetic patient does not mean the drug is failing. It means the biology is more complicated than a TikTok transformation video will ever show you.